Highlights
Recent surveillance data from the World Health Organization Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) for 2023 reveal a troubling landscape for the treatment of Neisseria gonorrhoeae. Key highlights include:
- Ceftriaxone resistance has emerged as a significant threat, particularly in Cambodia (15.3%) and Viet Nam (20.4%).
- Ciprofloxacin resistance is now near-universal across the nine sentinel countries, reaching 95.3%.
- Domestic travel within the previous 30 days was identified as a significant independent risk factor for harboring ceftriaxone-resistant isolates.
- The expansion of EGASP to include extragenital sampling and whole-genome sequencing is vital for tracking the global dissemination of resistant strains.
Background and the Global Burden of Gonorrhea
Neisseria gonorrhoeae remains a major global public health challenge, with an estimated 82 million new cases occurring annually among adults worldwide. As a highly adaptable pathogen, it has successfully developed resistance to every class of antimicrobial used for treatment, including sulfonamides, penicillins, tetracyclines, macrolides, and fluoroquinolones. Currently, the global standard of care relies on extended-spectrum cephalosporins (ESCs), specifically ceftriaxone, often administered as a single intramuscular dose.
The emergence of ‘super-gonorrhea’—strains with high-level resistance to ceftriaxone and multi-drug resistance to other options—threatens the viability of current empiric treatment protocols. In response, the World Health Organization (WHO) established the Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) to provide more granular, high-quality data than traditional surveillance. This programme focuses on standardized antimicrobial susceptibility testing (AST) linked with clinical and epidemiological patient metadata to better understand the drivers of resistance.
Study Design and Methodology
The 2023 EGASP retrospective observational study analyzed data from nine sentinel countries across three WHO regions: the Western Pacific (Cambodia, Philippines, Viet Nam), Southeast Asia (Indonesia, Thailand), and Africa (Malawi, South Africa, Uganda, Zimbabwe). The study population primarily consisted of men presenting with symptomatic urethral discharge.
In total, 3,498 men were enrolled, yielding 2,491 gonococcal isolates for analysis. Laboratory procedures utilized the Etest (bioMérieux) to determine the Minimum Inhibitory Concentrations (MICs, mg/L) for ceftriaxone, cefixime, azithromycin, gentamicin, and ciprofloxacin. Resistance was defined based on the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints. To identify factors associated with antimicrobial resistance (AMR), researchers employed univariable and multivariable logistic regression analyses to calculate odds ratios (OR) and adjusted odds ratios (aOR).
Key Findings: A Geography of Resistance
Ceftriaxone and Cefixime Resistance
The most alarming finding of the 2023 report is the concentration of ceftriaxone resistance in the Western Pacific Region. While the overall global resistance rate for ceftriaxone was 3.8% (95% CI 3.1–4.6%), this figure is skewed by extreme geographic variation. Notably, all 95 ceftriaxone-resistant isolates identified in the study originated from just two countries: Cambodia (15.3%) and Viet Nam (20.4%). In these nations, the resistance levels have far surpassed the 5% threshold at which the WHO recommends changing national first-line empiric treatment guidelines.
Cefixime resistance followed a similar pattern, with an overall resistance rate of 8.9%. Again, the highest prevalence was observed in the Western Pacific sentinel sites, suggesting that oral cephalosporins are increasingly ineffective in these regions.
Azithromycin and Ciprofloxacin Resistance
Azithromycin resistance remained relatively low but stable at 3.6% overall. However, the near-total loss of ciprofloxacin as a treatment option was confirmed, with a staggering 95.3% resistance rate across all participating countries. This underscores the obsolescence of fluoroquinolones for gonorrhea in most global contexts.
The Role of Patient Mobility
The epidemiological analysis provided critical insights into the spread of these resistant strains. In the multivariable analysis, traveling within the country during the previous 30 days was strongly associated with ceftriaxone resistance (aOR 4.12, 95% CI 2.65–6.65; p < 0.001). This suggests that internal migration and mobile populations play a pivotal role in the dissemination of AMR within national borders, highlighting a need for targeted public health interventions in high-traffic hubs.
Clinical Implications and Expert Commentary
The findings from the 2023 EGASP report are a clarion call for infectious disease specialists and public health officials. The high prevalence of ceftriaxone resistance in Cambodia and Viet Nam is particularly concerning because ceftriaxone is the ‘last line’ of effective monotherapy. If these strains continue to spread across borders, we may face an era of untreatable gonorrhea.
Clinical experts note that the current reliance on syndromic management in many resource-limited settings may inadvertently contribute to resistance by providing suboptimal or unnecessary antibiotic exposure. The implementation of test-of-cure (ToC) protocols is essential, particularly in regions where resistance is documented, to ensure clinical resolution and identify potential treatment failures early.
Furthermore, the study highlights the limitations of focusing solely on urethral samples from men. As many gonococcal infections in women and extragenital infections (pharyngeal and rectal) in men who have sex with men (MSM) are asymptomatic, these reservoirs can facilitate the silent spread and evolution of AMR. The expansion of EGASP to include extragenital sampling is a vital step toward a more comprehensive understanding of the N. gonorrhoeae landscape.
The Future Pipeline: Zoliflodacin and Gepotidacin
With the efficacy of cephalosporins waning, the medical community is looking toward novel antimicrobials. Two promising candidates are currently in late-stage development:
- Zoliflodacin: A first-in-class type II topoisomerase inhibitor. Recent Phase 3 trial results demonstrated that zoliflodacin was non-inferior to the combination of ceftriaxone and azithromycin for treating uncomplicated gonorrhea.
- Gepotidacin: A novel triazaacenaphthylene antibiotic that inhibits bacterial DNA replication. It is currently being evaluated for various bacterial infections, including gonorrhea.
While these drugs offer hope, their eventual introduction must be accompanied by strict antimicrobial stewardship to prevent the rapid emergence of new resistance mechanisms.
Conclusion
The 2023 WHO EGASP report confirms that antimicrobial resistance in Neisseria gonorrhoeae is not a future threat, but a present reality. The high levels of ceftriaxone resistance in Southeast Asia are a sentinel event for the rest of the world. Moving forward, the global health community must prioritize the expansion of standardized surveillance, the integration of whole-genome sequencing to track transmission pathways, and the rapid transition to novel therapeutic agents where current treatments fail. Without a coordinated, evidence-based response, the management of this common sexually transmitted infection could become increasingly complex and costly.
Funding and Acknowledgments
The WHO EGASP is funded by the World Health Organization and the Global Fund to Fight AIDS, Tuberculosis and Malaria. The authors acknowledge the contributions of the ministries of health and the laboratory staff in the nine sentinel countries.
References
1. Maatouk I, et al. Antimicrobial resistance in Neisseria gonorrhoeae in nine sentinel countries within the World Health Organization Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP), 2023: a retrospective observational study. Lancet Reg Health West Pac. 2025;61:101663. doi:10.1016/j.lanwpc.2025.101663.
2. Unemo M, et al. Update on the management and resistance of Neisseria gonorrhoeae. Nature Reviews Urology. 2021;18:425–443.
3. Wi T, et al. Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action. PLoS Med. 2017;14(7):e1002344.
